Penumbra, Inc. (PEN)
NYSE: PEN · Real-Time Price · USD
291.68
-11.44 (-3.77%)
Feb 21, 2025, 4:00 PM EST - Market closed
Penumbra Revenue
In the year 2024, Penumbra had annual revenue of $1.19B with 12.86% growth. Penumbra had revenue of $315.52M in the quarter ending December 31, 2024, with 10.83% growth.
Revenue (ttm)
$1.19B
Revenue Growth
+12.86%
P/S Ratio
9.43
Revenue / Employee
$265,470
Employees
4,500
Market Cap
11.23B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.19B | 136.09M | 12.86% |
Dec 31, 2023 | 1.06B | 211.39M | 24.95% |
Dec 31, 2022 | 847.13M | 99.54M | 13.32% |
Dec 31, 2021 | 747.59M | 187.18M | 33.40% |
Dec 31, 2020 | 560.41M | 13.01M | 2.38% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PEN News
- 17 hours ago - Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors - PRNewsWire
- 2 days ago - Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook - Benzinga
- 3 days ago - Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 4 weeks ago - Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025 - PRNewsWire
- 7 weeks ago - Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst - Benzinga
- 3 months ago - Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference - PRNewsWire